Blockade of calcium entry in smooth muscle cells by the antidepressant imipramine.
The present study was designed to evaluate the effects of antidepressants on smooth muscle contractile activity. In rat aortic rings, the antidepressants imipramine, mianserin and sertraline provoked concentration-dependent inhibitions of the mechanical responses evoked by K+ (30 mM) depolarization. These myorelaxant effects were not modified by the presence of glibenclamide or 80 mM K+ in the bathing medium. Moreover, the vasodilator properties of imipramine were not affected by atropine, phentolamine and pyrilamine. Radioisotopic experiments indicated that imipramine failed to enhance 86Rb outflow from prelabelled and perifused aortic rings whilst counteracting the increase in 45Ca outflow provoked by a rise in the extracellular K+ concentration. Simultaneous measurements of contractile activity and fura-2 fluorescence revealed that, in aortic rings, imipramine reduced the mechanical and fluorimetric response to K+ challenge. In A7r5 smooth muscle cells, whole cell recordings further demonstrated that imipramine inhibited the inward Ca2+ current. Under different experimental conditions, the ionic and relaxation responses to the antidepressants were reminiscent of those mediated by the Ca2+ entry blocker verapamil. Lastly, it should be pointed out that imipramine exhibited a myorelaxant effect of similar amplitude on rat aorta and on rat distal colon. All together, these findings suggest that the myorelaxant properties of imipramine, and probably also setraline and mianserin, could result from their capacity to inhibit the voltage-sensitive Ca2+ channels.
Laboratory of Pharmacology and Experimental Hormonology, Faculty of Medicine (CP 617), Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium.
Bénédicte
B
Becker
Nicole
N
Morel
Anne-Marie
AM
Vanbellinghen
Philippe
P
Lebrun
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001011:Aorta; D002118:Calcium / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000378:metabolism; D003106:Colon / Q000187:drug effects / Q000502:physiology; D004338:Drug Combinations; D005260:Female; D007099:Imipramine / Q000494:pharmacology*; D008803:Mianserin / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D032389:Myocytes, Smooth Muscle / Q000187:drug effects* / Q000378:metabolism; D010656:Phenylephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012413:Rubidium / Q000378:metabolism; D020280:Sertraline / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D000928:Antidepressive Agents; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D004338:Drug Combinations; D010656:Phenylephrine; D008803:Mianserin; D011189:Potassium Chloride; D014700:Verapamil; D012413:Rubidium; D007099:Imipramine; D020280:Sertraline; D002118:Calcium